Skip to content
★ Sign in to follow
CD

C4X Discovery Holdings plc Stock: price and insider trades · United Kingdom

ISIN GB00BQQ2RV18GB·

No insider purchase over the last 90 days. The latest, by Clive Dix, was filed 17 Apr 2018.

C4X Discovery Holdings plc: what insiders have been doing

C4X Discovery Holdings plc is a listed company. Filings by its managers are published through RNS (LSE). The past year has been quiet: not a single insider filing for C4X Discovery Holdings plc. The previous disclosure was published on 17 April 2018.

Looking back to 2016, when coverage begins, insiders filed 3 purchases and no sales.

Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.

Insider Decl.
3
Thresholds
n/a
Buy Volume
€160,379
3 ops. · all time
Sell Volume
n/a
n/a

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Last declaration on 17 April 2018
Declarations3 total
  • ▲
    Chief Executive Officer, DirectorExecutives
    79,100 GBP28FCA-NSM
    70,000 shares@ £1.1357.0% of flowLondon Stock Exchange - AIMISIN GB00BQQ2RV18FCA-NSM:LSE20180417125013_13607811_20200330111353276_11895
    Canonical exit: 16 Jul 2018 (T+90)
  • ▲
    Chief Executive Officer, DirectorExecutives
    20,300 GBP23FCA-NSM
    20,000 shares@ £1.01514.7% of flowLondon Stock Exchange - AIMISIN GB00BQQ2RV18FCA-NSM:LSE20180417070007_13606690_20200330111353385_12642
    Canonical exit: 15 Jul 2018 (T+90)
  • ▲
    Chief Executive Officer, DirectorExecutives
    38,800 GBP30FCA-NSM
    40,000 shares@ £0.97100.0% of flowLondon Stock Exchange - AIMISIN GB00BQQ2RV18FCA-NSM:LSE20161130142500_013051869_20200330143613321_23582
    Canonical exit: 28 Feb 2017 (T+90)

3 of 3 declarations

About C4X Discovery Holdings plc

C4X Discovery Holdings plc is a UK biotechnology company focused on drug discovery. It employs advanced technologies to identify new therapeutic targets and develop innovative treatments.